首页> 外文期刊>Internal and Emergency Medicine >Influence of the previous use of β-blockers on the early clinical course of acute coronary syndromes
【24h】

Influence of the previous use of β-blockers on the early clinical course of acute coronary syndromes

机译:先前使用β受体阻滞剂对急性冠脉综合征早期临床过程的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Recent studies have recently questioned the current role of β-blockers in myocardial infarction. Our purpose is to analyze the influence of the previous use of β-blockers on the early course of patients admitted because of acute coronary syndrome (ACS). We analyzed the data of 37.359 patients included in the ARIAM-Andalucia Registry. Of them, 7759 (20.8 %) were previously receiving β-blockers. BB patients were older, more often female, had more risk factors and vascular disease, and less often had an ST-elevation myocardial infarction. In the unadjusted analysis, BB patients less often had ventricular fibrillation or atrioventricular block, and more often a Killip classification >1, and no difference of in-hospital mortality (5.7 vs 5.6 %). After logistic regression analysis and propensity score matching, no differences in complications or mortality (odds ratio 0.997, 95 % confidence interval 0.882–1.128) were found in relationship to previous β-blockers. In conclusion, we find that the previous administration of β-blockers is not an independent predictor of the early prognosis of ACS.
机译:最近的研究最近质疑了β受体阻滞剂在心肌梗塞中的当前作用。我们的目的是分析先前使用β受体阻滞剂对因急性冠脉综合征(ACS)入院的患者早期病程的影响。我们分析了ARIAM-安达卢西亚注册中心中37.359例患者的数据。其中有7759名(20.8%)以前接受过β受体阻滞剂。 BB患者年龄较大,女性较多,有更多的危险因素和血管疾病,较少发生ST抬高型心肌梗死。在未经调整的分析中,BB患者较少出现心室纤颤或房室传导阻滞,而Killip分类> 1的频率较高,院内死亡率无差异(5.7 vs 5.6%)。经过logistic回归分析和倾向评分匹配后,发现与先前的β受体阻滞剂无关,并发症或死亡率无差异(几率0.997,95%置信区间0.882-1.128)。总之,我们发现以前服用β受体阻滞剂不是ACS早期预后的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号